1. FRI0063 Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomised controlled cohort of patients with rheumatoid arthritis. (1st June 2001) Authors: Bresnihan, B; Newmark, RD; Robbins, S; McCabe, D; Genant, HK Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0067 Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis. (1st June 2001) Authors: Genant, HK; Bresnihan, B; Ng, E; Robbins, S; Newmark, RD; McCabe, D Journal: Annals of the rheumatic diseases Issue: Volume 60(2001)Supplement 1 Page Start: A473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0186 Effects of denosumab, a subcutaneous rankl inhibitor, on the progression of structural damage in japanese patients with rheumatoid arthritis treated with csdmards: results from the 12-month double blind phase 3, desirable study. (15th June 2017) Authors: Takeuchi, T; Tanaka, Y; Soen, S; Yamanaka, H; Yoneda, T; Tanaka, S; Nitta, T; Okubo, N; Genant, HK; Heijde, D van der Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 841 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗